Triple negative breast cancer-review of current and emerging therapeutic strategies

Tarah Ballinger, Jill Kremer, Kathy Miller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Triple negative breast cancer (TNBC) is associated with a poor prognosis compared to other types of breast cancer. The classification of 'triple negative' is not one homogenous tumor type, but rather is made up of multiple molecularly and biologically diverse tumor subtypes. At present, no approved targeted therapy exists and the standard remains cytotoxic chemotherapy. The identification of TNBC subtypes has provided a basis for identifying possible targeted therapeutic options. In addition, the recognition that some TNBCs share characteristics similar to tumors arising in patients with germline BRCA mutations has led to consideration of DNA damaging agents as a potential treatment option. Multiple investigational approaches are also underway, including immune checkpoint inhibition, poly (ADP-ribose) polymerase inhibition, and androgen receptor blockage. The limited options available for systemic treatment of TNBC will hopefully expand as more is learned about the complex biology and molecular targets of this group of breast cancers. This review will discuss the biology of TNBC, current treatment options, and promising experimental strategies.

Original languageEnglish (US)
Pages (from-to)112-117
Number of pages6
JournalEuropean Oncology and Haematology
Volume12
Issue number2
DOIs
StatePublished - 2016

Fingerprint

Triple Negative Breast Neoplasms
Breast Neoplasms
Therapeutics
Neoplasms
Poly(ADP-ribose) Polymerases
Germ-Line Mutation
Androgen Receptors
Molecular Biology
Drug Therapy
DNA

Keywords

  • Breast cancer
  • Therapeutics
  • Triple negative

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Triple negative breast cancer-review of current and emerging therapeutic strategies. / Ballinger, Tarah; Kremer, Jill; Miller, Kathy.

In: European Oncology and Haematology, Vol. 12, No. 2, 2016, p. 112-117.

Research output: Contribution to journalArticle

@article{a7e8856c6b74436da2a277a29723bf47,
title = "Triple negative breast cancer-review of current and emerging therapeutic strategies",
abstract = "Triple negative breast cancer (TNBC) is associated with a poor prognosis compared to other types of breast cancer. The classification of 'triple negative' is not one homogenous tumor type, but rather is made up of multiple molecularly and biologically diverse tumor subtypes. At present, no approved targeted therapy exists and the standard remains cytotoxic chemotherapy. The identification of TNBC subtypes has provided a basis for identifying possible targeted therapeutic options. In addition, the recognition that some TNBCs share characteristics similar to tumors arising in patients with germline BRCA mutations has led to consideration of DNA damaging agents as a potential treatment option. Multiple investigational approaches are also underway, including immune checkpoint inhibition, poly (ADP-ribose) polymerase inhibition, and androgen receptor blockage. The limited options available for systemic treatment of TNBC will hopefully expand as more is learned about the complex biology and molecular targets of this group of breast cancers. This review will discuss the biology of TNBC, current treatment options, and promising experimental strategies.",
keywords = "Breast cancer, Therapeutics, Triple negative",
author = "Tarah Ballinger and Jill Kremer and Kathy Miller",
year = "2016",
doi = "10.17925/OHR.2016.12.02.89",
language = "English (US)",
volume = "12",
pages = "112--117",
journal = "European Oncology and Haematology",
issn = "2045-5275",
publisher = "Touch Digital Media",
number = "2",

}

TY - JOUR

T1 - Triple negative breast cancer-review of current and emerging therapeutic strategies

AU - Ballinger, Tarah

AU - Kremer, Jill

AU - Miller, Kathy

PY - 2016

Y1 - 2016

N2 - Triple negative breast cancer (TNBC) is associated with a poor prognosis compared to other types of breast cancer. The classification of 'triple negative' is not one homogenous tumor type, but rather is made up of multiple molecularly and biologically diverse tumor subtypes. At present, no approved targeted therapy exists and the standard remains cytotoxic chemotherapy. The identification of TNBC subtypes has provided a basis for identifying possible targeted therapeutic options. In addition, the recognition that some TNBCs share characteristics similar to tumors arising in patients with germline BRCA mutations has led to consideration of DNA damaging agents as a potential treatment option. Multiple investigational approaches are also underway, including immune checkpoint inhibition, poly (ADP-ribose) polymerase inhibition, and androgen receptor blockage. The limited options available for systemic treatment of TNBC will hopefully expand as more is learned about the complex biology and molecular targets of this group of breast cancers. This review will discuss the biology of TNBC, current treatment options, and promising experimental strategies.

AB - Triple negative breast cancer (TNBC) is associated with a poor prognosis compared to other types of breast cancer. The classification of 'triple negative' is not one homogenous tumor type, but rather is made up of multiple molecularly and biologically diverse tumor subtypes. At present, no approved targeted therapy exists and the standard remains cytotoxic chemotherapy. The identification of TNBC subtypes has provided a basis for identifying possible targeted therapeutic options. In addition, the recognition that some TNBCs share characteristics similar to tumors arising in patients with germline BRCA mutations has led to consideration of DNA damaging agents as a potential treatment option. Multiple investigational approaches are also underway, including immune checkpoint inhibition, poly (ADP-ribose) polymerase inhibition, and androgen receptor blockage. The limited options available for systemic treatment of TNBC will hopefully expand as more is learned about the complex biology and molecular targets of this group of breast cancers. This review will discuss the biology of TNBC, current treatment options, and promising experimental strategies.

KW - Breast cancer

KW - Therapeutics

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=85006380284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006380284&partnerID=8YFLogxK

U2 - 10.17925/OHR.2016.12.02.89

DO - 10.17925/OHR.2016.12.02.89

M3 - Article

VL - 12

SP - 112

EP - 117

JO - European Oncology and Haematology

JF - European Oncology and Haematology

SN - 2045-5275

IS - 2

ER -